ReviewThe Journal of clinical and aesthetic dermatology2021
Safety and Sourcing of Topical Cannabinoids: Many Questions, Few Answers.
Review in The Journal of clinical and aesthetic dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician.Pain medicine (Malden, Mass.) · 2026Review
- Article
- Commercial Cannabidiol for Community-Based Young Adolescents: Predicting Medicinal Use.Cannabis and cannabinoid research · 2025Article
- Comprehensive Insight into Cutaneous Application of Hemp.Pharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTopical cannabinoid products are increasingly being recommended and used for a variety of dermatologic conditions. Despite this, safety and efficacy data of topical preparations are lacking, and the differences between topical and oral formulations are not well characterized.
objectiveWe reviewed the literature to gather published data on topical cannabinoid products and the differences between topical and oral formulations.
methodsThe PubMed/MEDLINE literature database was searched using the terms "cannabinoids," "cannabidiol," "CBD," "topical cannabidiol," "transdermal cannabidiol," "hemp" and "skin." Results were manually screened to identify published data on topical formulations of cannabinoids or cannabidiol use, adverse effects, sourcing, and solubility.
resultsTopical formulations of cannabinoids might be more nuanced than oral formulations, due not only to dosing differences, but also to potential differences in transcutaneous absorption. Safety and efficacy might need to be evaluated on a product-by-product basis until universal standards for topical preparations are better established.
Indexed as
Identifiers
34840658PMC8570654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.